X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

ADVM

Closed

Adverum Biotechnologies Inc

2.28
+0.13 (+6.05%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 2.15
Day's Range: 2.11 - 2.365
Send
When Written:
 
0.722
Adverum Biotechnologies Inc. is a clinical-stage gene therapy company that is focused on developing treatments for ocular and rare diseases. The company was founded in 2006 and is headquartered in Redwood City, California. Adverum's lead product candidate is ADVM-022, a gene therapy for the treatment of wet age-related macular degeneration (AMD). The company is also developing gene therapies for the treatment of rare diseases such as alpha-1 antitrypsin deficiency and hereditary angioedema. Adverum has partnerships with Regeneron Pharmaceuticals and Editas Medicine to develop gene therapies for ocular diseases. The company went public in 2014 and is traded on the NASDAQ under the ticker symbol ADVM.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X